To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT

Launched by JINLING HOSPITAL, CHINA · Jan 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging method called 18F-LNC1007 injection PET/CT to see how well it works for diagnosing tumors, checking if they are in the early stages, or monitoring if they come back after treatment. The goal is to compare this new method with the standard imaging technique, 18F-FDG PET/CT, to find out which one provides better information for doctors. The trial will also check if the new injection is safe for patients.

To participate in this trial, you need to be at least 18 years old and either have a suspected or confirmed tumor. You should be in a stable condition, meaning your doctors think you have at least three months to live, and you must be able to lie still for about an hour during the scan. However, people with certain health issues, allergies to the injection, or who are pregnant or breastfeeding cannot join. If you do participate, you can expect to have some imaging tests done to help researchers learn more about how well this new method works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Age ≥18 years old; (2) Clinically suspected or confirmed tumor patients; (3) As judged by doctors, the expected survival time is 3 months; (4) Voluntarily sign informed consent; (5) Willing and able to follow the research protocol; (6) The subject must be able to lie on the scanning bed for at least 1 hour.
• Exclusion Criteria:
• • (1) known allergic history to 18F-LNC1007 injection; (2) Patients who cannot tolerate intravenous drug administration (such as needle fainting and blood fainting history); (3) Those who are not suitable for PET/CT and other imaging examinations or cannot complete them due to special reasons, including claustrophobia and radiophobia; (4) pregnant and lactating women; (5) Workers who are exposed to radiation for a long period of time; (6) serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis; (7) Participating in other interventional clinical trials within 1 month before screening; (8) Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy; (9) There are other circumstances that the researcher considers inappropriate to participate in this study.